VM 200

Drug Profile

VM 200

Alternative Names: VM200

Latest Information Update: 08 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Case Western Reserve University
  • Developer Vision Medicines
  • Class Amines; Eye disorder therapies; Small molecules
  • Mechanism of Action Aldehyde inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inborn error metabolic disorders; Macular degeneration; Sjogren-Larsson syndrome; Stargardt disease

Most Recent Events

  • 08 Jan 2016 Preclinical trials in Inborn error metabolic disorders in USA (PO) before January 2016
  • 08 Jan 2016 Preclinical trials in Macular degeneration in USA (PO) before January 2016
  • 08 Jan 2016 Preclinical trials in Sjogren-Larrson syndrome in USA (PO) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top